TEVA completes $3bn refinancing
TEVA Pharmaceuticals, an Israel-based drug company, signed a new $3bn five year unsecured revolving credit facility on Tuesday that replaces its existing smaller loan.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: